The Microrchidia CW-type zinc finger 2 (MORC2) gene encodes a protein expressed in all tissues and enriched in the brain. It is involved in Charcot-Marie-Tooth disease, with mire than 30 families presenting MORC2 mutations. Recently, MORC2 mutation have been shown to be responsible for more complex phenotypes like DIFGAN: developmental delay, impaired growth, dysmorphic facies and axonal neuropathy. Different mutations are responsible from a diverse spectrum of phenotype, from CMT to DIFGAN. MORC2 is involved, through its ATPase activity, in DNA repair, chromatin remodeling and epigenetic silencing via the Human silencing hub (HUSH) complex. Our hypothesis is that the hypo- or hyper-activation of the HUSH complex by different MORC2 mutations could be responsible for different phenotypes in patients. The aim of this study is to perform a genotype-phenotype correlation study in patients presenting MORC2 mutations.
Study Type
OBSERVATIONAL
Enrollment
45
under the arm using a 3 mm punch, with local anaesthesia, in the investigating centres.
3 classical 4ml tubes samples per patients, using the routine blood sampling technique, in the investigating centres. For children, blood sampling volume will be adapted to the patient's weight according to L.1121-1 of the French public health code.
CHU de Besançon
Besançon, France
RECRUITINGCHRU Brest
Brest, France
RECRUITINGCHU Grenoble
Grenoble, France
RECRUITINGCH de Versailles
Le Chesnay, France
RECRUITINGService de Génétique moléculaire, pharmacogénétique, hormologie Hôpital Bicêtre
Le Kremlin-Bicêtre, France
RECRUITINGHospices Civils de Lyon
Lyon, France
RECRUITINGCHU Marseille
Marseille, France
RECRUITINGCHU de Nantes
Nantes, France
RECRUITINGCH Pitié Salpêtrière
Paris, France
RECRUITINGHôpital Necker
Paris, France
RECRUITING...and 2 more locations
Epigenetic biomarker levels
Quantification of epigenetic biomarkers in patient and control-derived cells (number of reads in patients vs controls)
Time frame: At inclusion
RNA-seq
quantification of specific mRNA sequences in patient-derived cells (RNA copy number in patient vs control)
Time frame: At inclusion
Detection and quantification of specific nucleic acid biomarkers in patient's serum
Quantification of nucleic acid biomarkers in the patient's serum (number of reads in patients vs control)
Time frame: At inclusion
Quantification of nucleic acid biomarkers in patient's cerebrospinal fluid
Quantification of nucleic acid biomarkers in the patient's cerebrospinal fluid (CSF) (number of reads in patients vs control)
Time frame: At inclusion
Quantification of proteic biomarkers in patient's serum
Quantification of proteic biomarkers in the patient's serum (µg/mL)
Time frame: At inclusion
Quantification of proteic biomarkers in patient's cerebrospinal fluid (CSF)
Quantification of proteic biomarkers in the patient's cerebrospinal fluid (CSF)(µg/mL)
Time frame: At inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.